Skip to main content

Advertisement

SpringerLink
Log in

Outcome of hepatitis C–related liver transplantation in direct-acting antiviral era

  • Original Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Hepatitis C virus (HCV) has become an easily treatable disease after the introduction of sofosbuvir-based direct-acting antiviral (DAA) regimens. This is a large single center experience of changing severity and outcome profile of HCV-related liver disease after availability of DAAs.

Methods

A retrospective analysis of prospectively collected liver transplantation (LT) database of adults (age > 18 years at the time of LT) was performed from June 2010 to July 2018. A total of 410 patients (including 26 co-infection with hepatitis B) underwent LT for hepatitis C–related decompensated cirrhosis and/or hepatocellular carcinoma (HCC) out of 1754 adult transplantation in the defined period.

Results

The study group comprised of 296 males and 114 females aged 52.1 ± 7.9 years. HCV-related decompensated cirrhosis and/or HCC as indication of LT was present in 289/1016 (28.4%) during 2010–2014, which was reduced to 121/738 (16.3%) during 2015–2018 (p = 0.000). The LT recipients for HCV-related cirrhosis had significantly lower Child’s and model for end-stage liver disease (MELD) score during 2015–2018 as compared to that during 2010–2014; Child’s score was 7.9 ± 2.2 vs. 8.6 ± 2.1, p = 0.003; MELD score was 13.9 ± 5.3 vs. 17.1 ± 5.8, p = 0.000, respectively. There was a trend towards better survival in HCV patients during 2015–2018 as compared to that during 2010–2014. Significantly more patients had HCV RNA negative status before LT during 2015–2018 (38.8% vs. 13%, p = 0.000); moreover, the proportion of LT for decompensated cirrhosis (without HCC) decreased significantly in the latter period, 64.0% vs. 42.1% (p = 0.000).

Conclusion

In the DAA era, HCV as an indication for LT has decreased and patients have less severe disease at transplantation. There is a trend towards better patient survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.

    Article  CAS  Google Scholar 

  2. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470–7.

    Article  CAS  Google Scholar 

  3. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675–84.

    Article  CAS  Google Scholar 

  4. Everson G, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating disease regimen of antiviral therapy. Heptatology. 2005;42:255–62.

    Article  CAS  Google Scholar 

  5. Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated transplantation. J Hepatol. 2003;39:389–96.

    Article  CAS  Google Scholar 

  6. Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y, Sakhuja V. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. Trop Gastroenterol. 2012;33:189–92.

    Article  Google Scholar 

  7. Saigal S, Choudhary NS, Saraf N, et al. Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation. Indian J Gastroenterol. 2015;34:305–9.

    Article  Google Scholar 

  8. Guillouche P, Feray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther. 2011;33:163–74.

    Article  CAS  Google Scholar 

  9. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–59.

    Article  CAS  Google Scholar 

  10. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–28.

    Article  CAS  Google Scholar 

  11. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97.

    Article  CAS  Google Scholar 

  12. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–505.

    Article  CAS  Google Scholar 

  13. Fernández Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology. 2017;65:1810–22.

    Article  Google Scholar 

  14. Choudhary NS, Kumar A, Bodh V, et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol. 2017;36:113–6.

    Article  Google Scholar 

  15. Choudhary NS, Saigal S, Gautam D, et al. Efficacy and safety of sofosbuvir based regimens for treatment of hepatitis C recurrence after living donor liver transplantation: an experience from India. J Clin Exp Hepatol. 2018;8:121–4.

    Article  Google Scholar 

  16. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–31.

    Article  Google Scholar 

  17. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;10 Suppl 1:S14–8.

  18. Dumortier J, Boillot O, Scoazec JY. Recurrent hepatitis C after liver transplantation. World J Gastroenterol. 2014;20:11069–79.

    Article  Google Scholar 

  19. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–84.

    Article  CAS  Google Scholar 

  20. Qu Y, Guo Y, Li T, et al. Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients. J Gastroenterol Hepatol. 2017;32:740–8.

    Article  CAS  Google Scholar 

  21. Onaca NN, Levy MF, Sanchez EQ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl. 2003;9:117–23.

    Article  Google Scholar 

  22. Thuluvath PJ, Thuluvath AJ, Savva Y. Karnofsky performance status before and after liver transplantation predicts graft and patient survival. J Hepatol. 2018;69:818–25.

    Article  Google Scholar 

Download references

Acknowledgments

Mr. Yogesh Saini (research coordinator), Mr. Manish K Singh (biostatistician).

Author information

Authors and Affiliations

  1. Medanta Institute of Liver Transplantation and Regenerative Medicine, Medanta the Medicity Hospital, Sector 38, Gurugram, Delhi (NCR), 122 413, India

    Narendra S. Choudhary, Neeraj Saraf, Sanjiv Saigal, Amit Rastogi, Prashant Bhangui, Srinivas Thiagrajan & Arvinder S. Soin

Authors
  1. Narendra S. Choudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neeraj Saraf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanjiv Saigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amit Rastogi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prashant Bhangui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Srinivas Thiagrajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Arvinder S. Soin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NSC and NS: concept and initial draft; AR, PB, and ST: draft and data analysis; NS, SS, and AS: critical revision.

Corresponding author

Correspondence to Neeraj Saraf.

Ethics declarations

Conflict of interest

NSC, NS, SS, AR, PB, ST, and ASS declare that they have no conflict of interest.

Ethics statement

The study was performed conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.

Disclaimer

The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology, or the printer/publishers are responsible for the results/findings and content of this article.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choudhary, N.S., Saraf, N., Saigal, S. et al. Outcome of hepatitis C–related liver transplantation in direct-acting antiviral era. Indian J Gastroenterol 39, 539–543 (2020). https://doi.org/10.1007/s12664-020-01105-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-020-01105-z

Keywords

Search

Navigation